Bristol Myers Squibb (CELG-RI) Treasury Shares (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Treasury Shares of $43.5 billion for Q2 2026, little changed year-over-year from $43.6 billion in Q2 2025, and little changed quarter-over-quarter from $43.5 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Treasury Shares (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Treasury Shares for 18 consecutive years, with $43.5 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Treasury Shares changed 0.2% year-over-year to $43.5 billion; the TTM figure through Jun 2026 stood at $43.5 billion (changed 0.2% YoY), while the FY2025 annual figure was $43.6 billion, changed 0.17% from the prior year.
- Treasury Shares steadied at $43.5 billion in Q2 2026 per CELG-RI's latest filing, from $43.5 billion in the prior quarter.
- Across five years, Treasury Shares topped out at $902.0 million in Q4 2023 and bottomed at $788.0 million in Q2 2022.
- Historically, Treasury Shares has averaged $863.7 million across 5 years, with a median of $887.0 million in 2025.
- Annual changes were most pronounced in 2022 — Treasury Shares increased 29.37% — and 2024, when it retreated 0.25%.
- Bristol Myers Squibb's Treasury Shares stood at $38.6 billion in 2022, then advanced by 13.33% to $43.8 billion in 2023, then retreated by 0.25% to $43.7 billion in 2024, then fell by 0.17% to $43.6 billion in 2025, then dropped by 0.17% to $43.5 billion in 2026.
- Business Quant data shows CELG-RI's Treasury Shares at $43.5 billion in Q2 2026, $43.5 billion in Q1 2026, and $43.6 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 75.86 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 77.11 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.11 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 49.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 115.19 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | 43.50 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 43.50 Bn |
| Jun 30, 2026 | 880.00 Mn |
| Jun 30, 2026 | 43.50 Bn |
| Jun 30, 2026 | 880.00 Mn |
| Mar 31, 2026 | 43.52 Bn |
| Mar 31, 2026 | 881.00 Mn |
| Mar 31, 2026 | 43.52 Bn |
| Mar 31, 2026 | 881.00 Mn |
| Dec 31, 2025 | 43.58 Bn |
| Dec 31, 2025 | 43.58 Bn |
| Dec 31, 2025 | 887.00 Mn |
| Dec 31, 2025 | 887.00 Mn |
| Sep 30, 2025 | 43.59 Bn |
| Sep 30, 2025 | 887.00 Mn |
| Sep 30, 2025 | 887.00 Mn |
| Sep 30, 2025 | 43.59 Bn |
| Jun 30, 2025 | 888.00 Mn |
| Jun 30, 2025 | 43.59 Bn |
| Jun 30, 2025 | 43.59 Bn |
| Jun 30, 2025 | 888.00 Mn |